Medimo Oy
Medimo Oy is a privately held Finnish consulting firm providing pharmacovigilance, quality management, regulatory affairs, auditing, and marketing material review services to pharmaceutical and medical device companies across the Nordic countries and Europe.
- Company typePrivate
- Founded-
- HeadquartersTampere, Finland
- Headcount1–10
- GTM typeB2B
- OfferingServices
What Medimo Oy does
Medimo Oy is a privately held Finnish consulting firm headquartered in Tampere, founded by Anu Gummerus, that delivers specialized pharmacovigilance, quality management, regulatory affairs, auditing, and marketing material review services to pharmaceutical and medical device companies across the Nordic countries and broader Europe. The company operates with a remote team of seven named personnel distributed across four Finnish locations, providing services that span the full lifecycle of medicinal products — including EU QPPV responsibilities, QP batch release, marketing authorisation applications and maintenance, GVP/GMP/GDP auditing, promotional material review, and embedded consultant outsourcing. Pricing is structured on either monthly retainer or hourly billing bases per individual consulting contract, with multi-year engagements typical for ongoing QPPV and outsourcing functions.
The underlying technology stack is essentially human expertise: there is no proprietary software platform, AI tooling, or productized technology. Medimo's competitive positioning relies on the deep regulatory credentials of its personnel — including a former EU QPPV with 20+ years' experience, a Qualified Person with ATMP and sterile product expertise, a former European Medicines Agency contributor, and a pharmacist-toxicologist — together with documented specialization in Nordic local regulatory requirements that few competitors can match. Distribution occurs entirely through direct B2B sales, complemented by content marketing (bilingual blog, LinkedIn), industry event participation, and referrals via the EuDRAcon pan-European consultancy network.
The business model is classic professional services consulting: revenue derives from billable consultant hours and retainer contracts, acquired through founder-led outreach, networking, and inbound contacts via the website and meeting booking. The company has no external investors, no parent entity, and no disclosed funding history. Medimo's customer base is split between pharmaceutical companies (primary) and medical device companies (primary), with use cases including EU QPPV outsourcing, batch release by QPs, literature monitoring across Nordic countries, deviation/CAPA process support, and audit preparation — all targeting compliance with GVP, GMP, GDP, and EU marketing authorisation regulations.
Medimo Oy firmographics
Firmographics- Name
- Medimo Oy
- Legal name
- Medimo Oy
- Website
- https://medimo.fi
- Company type
- Private
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- Medimo Oy is a privately held Finnish consulting firm providing pharmacovigilance, quality management, regulatory affairs, auditing, and marketing material review services to pharmaceutical and medical device companies across the Nordic countries and Europe.
- Ownership category
- akta.pro rank
Medimo Oy industry classification
Industry- Product category
- Pharmaceutical Regulatory Consulting
- NAICS
- Scientific Research and Development Services (5417)
- SIC
- Services-Health Services (8000)
- akta.pro primary industry
- Clinical Quality Assurance (GCP QA, TMF/QMS oversight) (HLAGAKAI)
- akta.pro secondary industry
- Medical Writing & Clinical Documentation FSP (HLAGAOAC)
Keywords
Where Medimo Oy is headquartered
LocationHeadquarters
- HQ city
- Tampere
- HQ country
- Finland
- HQ region
- Europe
Offices1 record
Markets served
Medimo Oy business model
Business model- GTM type
- B2B
- Offering type
- Services
- Cost components
- Personnel, Operations, Marketing or Sales, Technology or R&D
Revenue model
- Regulatory Affairs & Pharmacovigilance Consulting: Medimo provides consulting services across the full lifecycle of medicinal products, including pharmacovigilance, quality management, regulatory affairs, auditing, marketing material review, and outsourcing. Revenue is generated through professional consulting engagements, with pricing based on either monthly fees or hourly billing as noted in consulting contract discussions.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Other | Multi-year contract | Monthly fee or hourly billing consulting arrangements |
Go-to-market motion1 record
Distribution channels1 record
Marketing channels5 records
Medimo Oy product offering
Product offeringCore offering
Medimo Oy is a Finnish pharmaceutical consulting firm providing pharmacovigilance, quality management, regulatory affairs, auditing, marketing material review, and outsourcing services to pharmaceutical and medical device companies. Its services cover the entire medicinal product lifecycle, including EU QPPV responsibilities, drug batch release by Qualified Persons, GVP/GMP/GDP compliance auditing, marketing authorisation applications, and embedded consulting. The company specialises in Nordic local regulatory requirements and operates across Europe through the EuDRAcon network.
Product overview
Medimo Oy is a consulting and solution provider offering integrated pharmacovigilance, quality, and regulatory affairs services for the pharmaceutical industry. The company's portfolio consists of six interconnected service areas: Pharmacovigilance (covering GVP-compliant adverse event management, EU QPPV functions, and local Nordic pharmacovigilance contacts), Quality Services (encompassing GDP/GMP quality assurance and quality management system consulting), Auditing (GVP system audits and GMP/GDP compliance audits), Review of Promotional Material (ethical, medical, and linguistic review of marketing materials), Regulatory Affairs/Marketing Authorisations (marketing authorisation applications, maintenance, SmPC writing, and translations), and Outsourcing (placing expert consultants within client organisations). These services are designed to cover the entire lifecycle of medicinal products and medical devices, from development through market launch to post-authorisation maintenance, with particular expertise in Nordic country requirements.
Differentiator
Problem solved
Functional benefit
Products and services
- Pharmacovigilance (Lääketurvatoiminta) Good Vigilance Practice (GVP) compliant pharmacovigilance services covering the entire medicine lifecycle, including adverse event reporting, signal detection, PSMF management, EU QPPV responsibilities, and local pharmacovigilance contact services for human and veterinary medicinal products. Designed for pharmaceutical companies requiring outsourced pharmacovigilance functions.
- Quality Services (Laatupalvelut) Quality management and quality process consulting services including GDP (Good Distribution Practice) and GMP (Good Manufacturing Practice) quality assurance, deviation management, CAPA systems, and quality management system development and maintenance. Designed for pharmaceutical companies requiring quality compliance support.
- Auditing Comprehensive auditing services for pharmacovigilance systems (GVP audits), GMP-compliant audits of manufacturing plants, active substance plants, packaging material manufacturers, contract laboratories, and GDP-compliant distribution audits. Designed for pharmaceutical companies requiring compliance verification.
- Review of Promotional Material (Markkinoinnin valvonta) Review of promotional, marketing, and educational materials for medicinal products and medical devices, including ethical and medical reviews of marketing materials for prescription and OTC drugs, linguistic review, and compliance verification. Designed for pharmaceutical and medical device companies.
- Regulatory Affairs / Marketing Authorisations (Myyntiluvat) Complete marketing authorisation services for human and veterinary drugs including application preparation, MA maintenance, variations, renewals, SmPC and product information text writing, translations, and regulatory database updates. Designed for pharmaceutical companies requiring regulatory affairs support.
- Outsourcing (Ulkoistaminen) Staff outsourcing services providing expert consultants embedded within client companies for regulatory affairs, pharmacovigilance, and quality tasks, offering interactive collaboration and on-site support. Designed for pharmaceutical companies needing embedded regulatory expertise.
Companies that use Medimo Oy
Customer profileSegments2 records
Ideal customer profiles2 records
Medimo Oy technology and API
TechnologyTechnology focussed No
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Medimo Oy partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- EuDRAconcoreEuDRAcon is a pan-European network of independent regulatory affairs consultancy companies dealing with medicinal products, medical devices, cosmetics, and food supplements. Medimo is a member, acting as a local consultancy partner in Finland. Through the network, Medimo provides access to regulatory expertise across 28 EU member states and can respond to queries about Finnish local regulations concerning regulatory affairs, pharmacovigilance, and quality.
Scale indicators3 records
Recent moves3 records
Expansion highlights6 records
Medimo Oy competitors and assessment
Company assessmentBroad incumbents
- IQVIA: Global CRO and life sciences services giant offering regulatory, PV and quality services alongside broader clinical and commercial offerings. Represents the scaled incumbent Medimo competes against.
- Labcorp Drug Development: Global CRO offering regulatory, pharmacovigilance and quality services among a broad portfolio. Established incumbent competing for the same enterprise clients Medimo targets.
- Parexel: Major global CRO with regulatory affairs, pharmacovigilance and quality consulting capabilities. Provides the wider market context and competitive benchmark for Medimo.
- ICON plc: Large CRO with regulatory and pharmacovigilance service lines serving pharma clients globally. Broad incumbent in the same regulatory/quality consulting space.
Direct peers
- Navitas Life Sciences: Regulatory, pharmacovigilance and clinical services consultancy serving pharma and biotech clients. Closely comparable service offerings and client profile to Medimo.
- ProPharma Group: Regulatory compliance, pharmacovigilance and quality consulting firm serving pharma, biotech and medical device companies globally. Direct overlap with Medimo's core service lines.
- PharmaLex: Specialised regulatory affairs, pharmacovigilance and quality consulting firm serving pharma and medical device clients across Europe. Highly comparable service mix to Medimo, operating at much larger scale.
- Arriello: European pharmacovigilance, regulatory and quality consultancy focused on pharma and medical devices. Directly comparable GxP service portfolio and target client base to Medimo.
- Diamond Pharma Services: Pharmacovigilance, regulatory affairs and quality assurance consultancy supporting pharma clients. Direct competitor in the same niche consulting segment as Medimo.
- Inpharmation: Pharmaceutical regulatory affairs and pharmacovigilance consultancy with European footprint. Direct peer in the regulatory/PV specialist space.
Market position
Strengths4 records
Weaknesses4 records
Competitive moat3 records
Key risks5 records
Key highlights6 records
Customer concentration
Medimo Oy social profiles
Digital presenceMedimo Oy financial estimates
Financial estimateRevenue estimate
Valuation estimate
Medimo Oy leadership team
Management profileNumber of profiles
Profiles7 records
Medimo Oy funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Medimo Oy M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Medimo Oy
What does Medimo Oy do?
Medimo Oy is a Finnish pharmaceutical consulting firm providing pharmacovigilance, quality management, regulatory affairs, auditing, marketing material review, and outsourcing services to pharmaceutical and medical device companies. Its services cover the entire medicinal product lifecycle, including EU QPPV responsibilities, drug batch release by Qualified Persons, GVP/GMP/GDP compliance auditing, marketing authorisation applications, and embedded consulting. The company specialises in Nordic local regulatory requirements and operates across Europe through the EuDRAcon network.
Is Medimo Oy a public or private company?
Medimo Oy is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was Medimo Oy founded?
Medimo Oy was founded in -1. It employs 1 to 10 people.
Where is Medimo Oy based?
Medimo Oy is headquartered in Tampere, Finland, in the Europe region.
How does Medimo Oy make money?
One revenue line is on record: regulatory Affairs & Pharmacovigilance Consulting.
Who are Medimo Oy's main competitors?
Broad incumbents on record are IQVIA, Labcorp Drug Development, Parexel and ICON plc. Direct peers are Navitas Life Sciences, ProPharma Group, PharmaLex, Arriello, Diamond Pharma Services and Inpharmation.
Does Medimo Oy have an API?
No public API is recorded for Medimo Oy.
What industry is Medimo Oy in?
Medimo Oy's product category is Pharmaceutical Regulatory Consulting. Its primary akta.pro industry code is HLAGAKAI, Clinical Quality Assurance (GCP QA, TMF/QMS oversight), with a secondary code of HLAGAOAC, Medical Writing & Clinical Documentation FSP. Its NAICS code is 5417 and its SIC code is 8000.